Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy
Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy
批准号:
10533472
负责人:
David Gius
金额:
$6.95万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-04-09 至 2026-03-31
关键词:
AcetylationAdjuvant TherapyAllograftingAndrogen ReceptorAutomobile DrivingBiological MarkersBiologyCellsCellular Metabolic ProcessChIP-seqChemical AgentsChemicalsClinical ResearchComplexDataDevelopmentDrug Metabolic DetoxicationExhibitsExposure toGeneticGoalsGrantIn VitroIonizing radiationLNCaPLeadLysineMalignant NeoplasmsMalignant neoplasm of prostateMeasurementMeasuresMediatingMetabolicMetabolismMitochondriaModelingMolecular TargetNatureOrganoidsPathway interactionsPeroxidasesPhenotypeProcessPropertyReactive Oxygen SpeciesReceptor SignalingReporterResistanceRoleSOD2 geneSignal TransductionSuperoxide DismutaseSuperoxidesSystemTestingTherapeuticTherapeutic InterventionTimeTissue RecombinationTumor Suppressor Proteinsandrogen deprivation therapyenzalutamidehigh riskin vivoin vivo Modelmenmitochondrial metabolismmouse modelmutantneoplastic cellnew therapeutic targetnovelnovel therapeutic interventionpatient derived xenograft modelprostate cancer cellradiation resistanceresponsesmall moleculestem cell biomarkersstem-like cellstemnesstherapy resistanttissue culturetranscriptome sequencingtumortumor growth
中文摘要
总结:这项新的R01应用的首要目标是研究线粒体的失调
英文摘要
SUMMARY - The overarching goal of this new R01 application is to investigate the dysregulation of mitochondrial
networks responsible for maintaining normal metabolism is an established hallmark of cancer. This disruption of
cellular metabolism, leads to the aberrant accumulation of reactive oxygen species (ROS), triggering
maladaptive signaling that is an emerging, novel mechanism leading to ionizing radiation (IR) resistance (IRR)
as well as enzalutamide (ENZ) resistance (ENZR). In this regard, recently identified a mitochondrial signaling
axis centered on manganese superoxide dismutase (MnSOD) which, when the acetylation (Ac) status of lysine
68 (K68-Ac) is altered, disrupts cellular metabolism, leading to aberrant ROS levels (Zhu, Nature Commun.,
2019). In addition, LNCaP cells expressing a MnSOD K68-Ac mimic mutant (MnSODK68Q) exhibited IRR/ENZR,
increased HIF2a, known to promote stemness properties, and two stem cell markers, Oct4 and SOX2. As such,
we seek to show that MnSOD-K68-Ac may drive IRR and/or ENZR, by altering MnSOD’s structural composition
and enzymatic activity, and in a broader context, tumor growth and survival via a cell stemness-like mechanism.
Finally, will GC4419 exposure, a chemical agent that acts as a MnSOD mimic, reverse the IRR/ENZR
phenotype? Thus, it is hypothesized that prostate tumor cells exposed to IRR and/or ENZR increase MnSOD-
K68-Ac, disrupting normal MnSOD biology at the cellular and mitochondrial level (i.e., aberrant ROS), which
initiates cellular reprogramming, via increased HIF2a, leading to lineage plasticity properties, a change in tumor
cell fate, and an IRR and/or ENZR tumor phenotype. It is also proposed that MnSOD-K68-Ac is a novel axis for
new therapeutic interventions in IRR and IRR/ENZR tumors. Finally, using GC4419, which that chemically
replaces MnSOD activity, we ask whether superoxide detoxification reverts/converts these IRR/ENZR prostate
tumor cells to a sensitive phenotype by restoring normal metabolism
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy
-
批准号:10737810
-
项目类别:
-
资助金额:$6.81万
-
财政年份:2021
-
负责人:David Gius
-
依托单位:
Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy
-
批准号:10390451
-
项目类别:
-
资助金额:$37.61万
-
财政年份:2021
-
负责人:David Gius
-
依托单位:
MnSOD-K68-Ac reprograms a lineage plasticity switch / stemness in ER+ breast malignancies
-
批准号:10327336
-
项目类别:
-
资助金额:$36.08万
-
财政年份:2021
-
负责人:David Gius
-
依托单位:
MnSOD-K68-Ac reprograms a lineage plasticity switch / stemness in ER+ breast malignancies.
-
批准号:10817556
-
项目类别:
-
资助金额:$5.07万
-
财政年份:2021
-
负责人:David Gius
-
依托单位:
Dys-regulation of the MnSOD-Ac-ROS-HIF2a axis promotes IR / Cisplatin resistance phenotype
-
批准号:10335424
-
项目类别:
-
资助金额:$38.95万
-
财政年份:2021
-
负责人:David Gius
-
依托单位:
MnSOD-K68-Ac reprograms a lineage plasticity switch / stemness in ER+ breast malignancies
-
批准号:10541193
-
项目类别:
-
资助金额:$36.08万
-
财政年份:2021
-
负责人:David Gius
-
依托单位:
Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy
-
批准号:10548835
-
项目类别:
-
资助金额:$37.61万
-
财政年份:2021
-
负责人:David Gius
-
依托单位:
Dys-regulation of the MnSOD-Ac-ROS-HIF2a axis promotes IR / Cisplatin resistance phenotype
-
批准号:10024964
-
项目类别:
-
资助金额:$7.28万
-
财政年份:2017
-
负责人:David Gius
-
依托单位:
Dys-regulation of the MnSOD-Ac-ROS-HIF2a axis promotes IR / Cisplatin resistance phenotype
-
批准号:9889066
-
项目类别:
-
资助金额:$39.02万
-
财政年份:2017
-
负责人:David Gius
-
依托单位:
Dys-regulation of the MnSOD-Ac-ROS-HIF2a axis promotes IR / Cisplatin resistance phenotype
-
批准号:9262705
-
项目类别:
-
资助金额:$39.65万
-
财政年份:2017
-
负责人:David Gius
-
依托单位:
ROS and HIFa as molecular targets for chemoprevention in Sirt3 -/- breast cancers
-
批准号:8401029
-
项目类别:
-
资助金额:$37.96万
-
财政年份:2012
-
负责人:David Gius
-
依托单位:
ROS and HIFa as molecular targets for chemoprevention in Sirt3 -/- breast cancers
-
批准号:8549177
-
项目类别:
-
资助金额:$35.68万
-
财政年份:2012
-
负责人:David Gius
-
依托单位:
ROS and HIFa as molecular targets for chemoprevention in Sirt3 -/- breast cancers
-
批准号:8704896
-
项目类别:
-
资助金额:$36.82万
-
财政年份:2012
-
负责人:David Gius
-
依托单位:
ROS and HIFa as molecular targets for chemoprevention in Sirt3 -/- breast cancers
-
批准号:8890802
-
项目类别:
-
资助金额:$37.96万
-
财政年份:2012
-
负责人:David Gius
-
依托单位:
ROS and HIFa as molecular targets for chemoprevention in Sirt3 -/- breast cancers
-
批准号:9114533
-
项目类别:
-
资助金额:$37.96万
-
财政年份:2012
-
负责人:David Gius
-
依托单位:
SIRT3 is a Mitochondrial Tumor Suppressor in ER/PR Positive Mammary Tumors
-
批准号:8547783
-
项目类别:
-
资助金额:$29.77万
-
财政年份:2011
-
负责人:David Gius
-
依托单位:
SIRT3 is a Mitochondrial Tumor Suppressor in ER/PR Positive Mammary Tumors
-
批准号:8703629
-
项目类别:
-
资助金额:$30.67万
-
财政年份:2011
-
负责人:David Gius
-
依托单位:
SIRT3 is a Mitochondrial Tumor Suppressor in ER/PR Positive Mammary Tumors
-
批准号:8050512
-
项目类别:
-
资助金额:$32.32万
-
财政年份:2011
-
负责人:David Gius
-
依托单位:
Loss of mtSIRT3, Decreased MnSOD Activity, and IR Induced Genomic Instability
-
批准号:8408793
-
项目类别:
-
资助金额:$36.77万
-
财政年份:2010
-
负责人:David Gius
-
依托单位:
Loss of Mitochondrial Sirt3, Decreased MnSOD Activity, and IR Induced Genomic Instability
-
批准号:8914122
-
项目类别:
-
资助金额:$36.27万
-
财政年份:2010
-
负责人:David Gius
-
依托单位:
海外基金